RxDoctor Payments Data

Josette Etienne

Family · Villa Rica, GANPI 1396138368

Payments from drug & device makers

$2,199in general payments, 2019–2025

Across 96 payments — averaging $22.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Vanda Pharmaceuticals Inc.$198
  • AstraZeneca$170
  • Lilly USA, LLC$137
  • Shockwave Medical, Inc$108
  • Electromed, Inc.$99
  • plus $384 from 13 others

What the payments were for

  • Food & beverage$2,199100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,199 in reported general payments places this provider in the 80th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$39,970
Medicare patients
83
Services billed
948

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide68$96,202
RybelsusSemaglutide25$29,837
EliquisApixaban13$21,549
LinzessLinaclotide23$17,487
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$13,389
Tresiba Flextouch U-100Insulin Degludec21$11,600
JardianceEmpagliflozin14$9,326
BelsomraSuvorexant11$4,802
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl21$4,283
Omega-3 Acid Ethyl Esters21$2,483
Perphenazine12$1,394
Albuterol Sulfate HfaAlbuterol Sulfate45$989
Nifedipine ErNifedipine31$724
Gabapentin55$683
Omeprazole66$616

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,102$126,03993 claims
AbbVieLinzess$53$17,48723 claims
AstraZenecaBreztri Aerosphere$170$13,38920 claims
Boehringer IngelheimJardiance$48$9,32614 claims
MerckBelsomra$18$4,80211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,258 family providers in Georgia.

Other family in Villa Rica

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →